查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1875958

基於次世代定序技術的RNA定序全球市場

NGS-Based RNA-Sequencing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球基於次世代定序(NGS) 的 RNA定序市場規模將達到 97 億美元。

全球基於次世代定序（NGS）的RNA定序市場規模預計在2024年為32億美元，到2030年將達到97億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為20.1%。本報告分析的細分市場之一「定序平台及耗材」預計將以20.7%的複合年成長率成長，並在分析期間結束時達到51億美元。同時，「樣本製備」細分市場預計在分析期間內將以17.4%的複合年成長率成長。

美國市場規模估計為8.736億美元，而中國市場預計將以18.6%的複合年成長率成長。

預計到2024年，美國基於次世代定序（NGS）技術的RNA定序市場規模將達到8.736億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到14億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到18.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期內，它們的複合年成長率將分別達到18.3%和17.1%。在歐洲，德國預計將以約14.3%的複合年成長率成長。

全球基於NGS的RNA定序市場—主要市場趨勢與促進因素概述

什麼是基於次世代定序（NGS）的RNA定序？為什麼它正在徹底改變基因組學領域？

基於次世代定序（NGS）的RNA定序（RNA-Seq）是一種高通量技術，它使科學家能夠以前所未有的解析度分析整個轉錄組，並識別和定量樣本中的RNA分子。此方法使研究人員能夠探索基因表現、檢測新的轉錄物並揭示可變剪接事件，這對於理解細胞功能至關重要。與傳統定序技術不同，基於NGS的RNA-Seq能夠提供更全面的轉錄組視圖，幫助腫瘤學、神經病學和免疫學等領域的研究人員更好地了解疾病並開發新的治療方法。

基於次世代定序技術的RNA定序意義重大，其能夠捕捉不同組織、發育階段和疾病狀態下基因表現的動態變化。透過揭示不同環境下基因調控與表現的機制，RNA定序在生物標記發現、藥物研發和精準醫療領域具有極高的應用價值。 RNA定序能夠研究環境因素、基因突變和治療性介入對基因活性的影響，使其成為基礎研究和臨床應用領域的創新工具。

基於次世代定序（NGS）的RNA定序市場正在如何發展？

由於技術進步和定序成本的下降，基於次世代定序（NGS）的RNA定序市場正在快速發展。其中一個關鍵趨勢是單細胞RNA定序（scRNA-Seq）的發展，它使研究人員能夠在單細胞層級分析基因表現。這項技術能夠更詳細地展現細胞異質性，從而發現組織內的稀有細胞類型、細胞狀態轉變以及免疫反應。 scRNA-Seq的整合應用在癌症研究等領域變得至關重要，因為了解腫瘤微環境和免疫細胞相互作用有助於開發更具靶向性的治療方法。

另一個重要趨勢是RNA定序在臨床診斷中的應用日益廣泛，尤其是在癌症和罕見遺傳疾病領域。隨著精準醫療的蓬勃發展，RNA定序正被用於識別疾病特異性的基因表現，從而指導治療決策。此外，雲端基礎平台的RNA定序資料分析應用也日益普及，使研究人員能夠更有效率地處理和解讀大型資料集。這些進步使得RNA定序能夠惠及更廣泛的研究人員和臨床醫生，進一步推動了其在學術界和商業領域的應用。

哪些產業正在主導基於NGS的RNA定序的應用？

基於新一代定序技術的RNA定序已在學術研究和製藥產業中廣泛使用。在生物醫學研究領域，大學和研究機構利用RNA定序技術研究多種疾病（包括癌症、心血管疾病和神經系統疾病）的基因表現模式。這項技術對於闡明疾病機制和識別潛在的治療標靶至關重要。尤其是在癌症研究領域，RNA定序技術的應用正主導癌基因、抑癌基因和抗藥性機制的發現。

在製藥和生物技術產業，RNA定序也是藥物發現和開發中重要的技術。製藥公司利用RNA定序來識別可用於新型治療方法的生物標記物，並監測臨床試驗中患者的反應。在臨床診斷領域，RNA定序正被整合到精準醫療計畫中，以根據患者獨特的基因和轉錄組特徵開發個人化治療方案。在農業領域，RNA定序也被用於改良作物和研究植物-病原體相互作用，凸顯了其跨產業的廣泛應用。

推動次世代定序（NGS）RNA定序市場成長要素是什麼？

基於次世代定序（NGS）的RNA定序市場成長受多種因素驅動，其中定序成本的下降是最重要的因素之一。隨著基因組定序成本的持續降低，RNA定序技術對研究人員和臨床醫生變得更加普及，從而在各個領域中廣泛應用。另一個主要促進因素是人們對個人化醫療的日益關注，個人化醫療高度依賴轉錄組數據來為每位患者制定量身定做的治療方法。 RNA測序能夠提供開發個人化療法所需的詳細基因表現訊息，尤其是在腫瘤學和罕見遺傳疾病領域。

單細胞RNA定序等技術進步也推動了市場成長，因為它們能夠對基因表現進行更詳細、更精確的分析。 RNA測序在臨床診斷領域的擴展也是一個關鍵因素，因為醫療機構擴大使用基於RNA的檢測方法來診斷疾病和監測治療效果。此外，人們對了解免疫系統和微生物組等複雜生物系統的興趣日益濃厚，也推動了對RNA測序的需求，因為RNA測序能夠提供關於基因調控和相互作用網路的深入見解。

部分：

按產品/服務（定序平台/耗材、樣品製備、定序服務、數據分析、儲存/管理）、按技術（合成定定序(SBS)、單分子即時定序 (SMRT)、離子半導體定定序、奈米孔定序）、按應用（研究中心/學術機構、醫院/診所、製藥/生物技術公司、其他應用）定序

受訪公司範例

  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有查詢LLM 或產業專用的SLM 的典型方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在地、製造地以及進出口（成品和OEM產品）情況，預測企業競爭地位的變化。這種複雜多變的市場現實會從多個方面影響競爭對手，包括增加銷貨成本、降低盈利和重組供應鏈，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP13599

Global NGS-Based RNA-Sequencing Market to Reach US$9.7 Billion by 2030

The global market for NGS-Based RNA-Sequencing estimated at US$3.2 Billion in the year 2024, is expected to reach US$9.7 Billion by 2030, growing at a CAGR of 20.1% over the analysis period 2024-2030. Sequencing Platforms & Consumables, one of the segments analyzed in the report, is expected to record a 20.7% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Sample Preparation segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$873.6 Million While China is Forecast to Grow at 18.6% CAGR

The NGS-Based RNA-Sequencing market in the U.S. is estimated at US$873.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global NGS-Based RNA-Sequencing Market - Key Trends & Drivers Summarized

What Is NGS-Based RNA-Sequencing and Why Is It Transformative for Genomics?

Next-Generation Sequencing (NGS)-based RNA sequencing (RNA-Seq) is a high-throughput technique that allows scientists to analyze the entire transcriptome, identifying and quantifying RNA molecules in a sample at unprecedented resolution. This method enables researchers to explore gene expression, detect novel transcripts, and uncover alternative splicing events that are critical for understanding cellular functions. Unlike traditional sequencing technologies, NGS-based RNA-Seq provides a more comprehensive view of the transcriptome, helping researchers in fields like oncology, neurology, and immunology advance their understanding of diseases and develop new therapies.

The significance of NGS-based RNA sequencing lies in its ability to capture a dynamic picture of gene expression across various tissues, stages of development, and disease conditions. It is instrumental in biomarker discovery, drug development, and precision medicine by offering insights into how genes are regulated and expressed in different contexts. With RNA-Seq, researchers can investigate how environmental factors, genetic mutations, or therapeutic interventions affect gene activity, making it a transformative tool in both basic research and clinical applications.

How Is the NGS-Based RNA-Sequencing Market Evolving?

The NGS-based RNA sequencing market is evolving rapidly, driven by technological advancements and decreasing costs of sequencing. One of the key trends is the development of single-cell RNA sequencing (scRNA-Seq), which allows researchers to analyze gene expression at the single-cell level. This technique provides a more granular view of cellular heterogeneity, enabling the discovery of rare cell types, cell-state transitions, and immune responses within tissues. The integration of scRNA-Seq is becoming essential in areas like cancer research, where understanding tumor microenvironments and immune cell interactions can lead to better-targeted therapies.

Another significant trend is the increasing application of RNA-Seq in clinical diagnostics, particularly for cancer and rare genetic diseases. As precision medicine initiatives gain momentum, RNA-Seq is being used to identify disease-specific gene expression signatures that can guide treatment decisions. Additionally, the use of cloud-based platforms for RNA-Seq data analysis is growing, allowing researchers to process and interpret large datasets more efficiently. These advancements are making RNA-Seq more accessible to a broader range of researchers and clinicians, further expanding its adoption in both academic and commercial settings.

Which Industries Are Leading the Adoption of NGS-Based RNA-Sequencing?

NGS-based RNA sequencing is being widely adopted in both academic research and the pharmaceutical industry. In biomedical research, universities and research institutions are using RNA-Seq to study gene expression patterns in various diseases, including cancer, cardiovascular diseases, and neurological disorders. This technology is critical for understanding disease mechanisms and identifying potential therapeutic targets. Cancer research, in particular, is leading the adoption of RNA-Seq as it enables the discovery of oncogenes, tumor suppressor genes, and drug resistance mechanisms.

The pharmaceutical and biotechnology industries are also significant adopters of RNA-Seq, leveraging it for drug discovery and development. Pharmaceutical companies use RNA-Seq to identify biomarkers that can be targeted by new therapies, as well as to monitor patient responses to treatments in clinical trials. In clinical diagnostics, RNA-Seq is being integrated into precision medicine programs to develop personalized treatments based on a patient's unique genetic and transcriptomic profile. The agricultural sector is also exploring RNA-Seq for crop improvement and the study of plant-pathogen interactions, highlighting its versatility across industries.

What Are the Key Growth Drivers in the NGS-Based RNA-Sequencing Market?

The growth in the NGS-based RNA sequencing market is driven by several factors, with the decreasing cost of sequencing being one of the most significant. As the cost per genome continues to drop, RNA-Seq is becoming more accessible to researchers and clinicians, leading to wider adoption across various fields. Another key driver is the increasing focus on precision medicine, which relies heavily on transcriptomic data to tailor treatments for individual patients. RNA-Seq provides the detailed gene expression information needed to develop personalized therapies, particularly in oncology and rare genetic disorders.

Technological advancements, such as single-cell RNA sequencing, are also propelling market growth by enabling more detailed and accurate analysis of gene expression. The expansion of RNA-Seq into clinical diagnostics is another important factor, as healthcare providers increasingly use RNA-based tests to diagnose diseases and monitor treatment responses. Additionally, the growing interest in understanding complex biological systems, such as the immune system and microbiome, is fueling demand for RNA-Seq as it offers deep insights into gene regulation and interaction networks.

SCOPE OF STUDY:

The report analyzes the NGS-Based RNA-Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services, Data Analysis, Storage & Management); Technology (Sequencing by Synthesis (SBS), Single-Molecule Real-time (SMRT) Sequencing, Ion Semiconductor Sequencing, Nanopore Sequencing); End-Use (Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • Illumina, Inc.
  • Macrogen, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • NGS-Based RNA-Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Next-Generation Sequencing (NGS) Technologies Drives Growth in RNA-Sequencing for Precision Medicine
    • Increasing Demand for RNA-Seq in Cancer Research Expands Opportunities for Biomarker Discovery and Targeted Therapies
    • Technological Advancements in Single-Cell RNA-Sequencing Propel Growth in Genomic Research and Cellular Analysis
    • Growing Use of NGS-Based RNA-Sequencing in Drug Development Fuels Market for High-Throughput Genomic Profiling
    • Rising Focus on Transcriptomics Expands Market for NGS-Based RNA-Sequencing in Understanding Gene Expression Patterns
    • Increasing Use of RNA-Sequencing in Neurodegenerative Disease Research Strengthens Demand in Neuroscience
    • Emerging Applications of RNA-Seq in Personalized Medicine Drive Growth in Precision Diagnostics and Therapeutic Development
    • Technological Innovations in NGS Platforms Strengthen Market for RNA-Sequencing in Multi-Omics and Systems Biology Studies
    • Growing Adoption of RNA-Seq in Infectious Disease Research Expands Market for Pathogen Identification and Vaccine Development
    • Rising Interest in RNA-Seq for Studying Non-Coding RNAs Expands Opportunities in Gene Regulation and Epigenetics Research
    • Advancements in Bioinformatics and Data Analysis Tools Propel Growth in RNA-Sequencing for Complex Data Interpretation
    • Increasing Use of RNA-Seq in Agricultural Genomics Expands Market for Crop Improvement and Livestock Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World NGS-Based RNA-Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for NGS-Based RNA-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Sequencing Platforms & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Sequencing Platforms & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Sample Preparation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Sample Preparation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sequencing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Sequencing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Data Analysis, Storage & Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Data Analysis, Storage & Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Sequencing by Synthesis (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Sequencing by Synthesis (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ion Semiconductor Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Ion Semiconductor Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Single-molecule Real-time (SMRT) Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Single-molecule Real-time (SMRT) Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Centers & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Research Centers & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • NGS-Based RNA-Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Product & Service - Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by Product & Service - Percentage Breakdown of Value Sales for Sequencing Platforms & Consumables, Sample Preparation, Sequencing Services and Data Analysis, Storage & Management for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by Technology - Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time (SMRT) Sequencing and Nanopore Sequencing for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for NGS-Based RNA-Sequencing by End-Use - Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for NGS-Based RNA-Sequencing by End-Use - Percentage Breakdown of Value Sales for Research Centers & Academic Institutes, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION